Tara O Henderson1, Brynn W Fowler1, Haley A Hamann1, Paul C Nathan2, Jillian Whitton3, Wendy M Leisenring3, Kevin C Oeffinger4, Joseph P Neglia5, Lucie M Turcotte5, Michael A Arnold6, Miriam R Conces7, Rebecca M Howell8, Leslie L Robison9, Gregory T Armstrong9, Kenneth A Alexander10. 1. Department of Pediatrics, University of Chicago Comer Children's Hospital, Chicago, Illinois. 2. Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada. 3. Fred Hutchinson Cancer Research Center, Seattle, Washington. 4. Duke Cancer Institute, Duke University, Durham, North Carolina. 5. Pediatric Hematology, Oncology, Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota. 6. Department of Pathology, Children's Hospital of Colorado, University of Colorado, Denver, Colorado. 7. Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio. 8. Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 9. Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee. 10. Pediatric Infectious Diseases, Nemours Children's Hospital, Orlando, Florida.
Abstract
BACKGROUND: Human papillomavirus (HPV)-associated subsequent malignant neoplasms (SMNHPV ) in childhood cancer survivors are poorly understood. METHODS: The cumulative risk of SMNHPV was assessed among 24,363 Childhood Cancer Survivor Study participants. Standardized incidence ratios (SIRs) and absolute excess risk were calculated using age-matched, sex-matched, and calendar year rates from the Surveillance, Epidemiology, and End Results program. Poisson regression models identified SMNHPV risk factors, evaluating relative SIRs (rSIR) and 95% confidence intervals (95% CIs). RESULTS: In total, 46 survivors developed an SMNHPV (median age, 31 years [range, 10-56 years]; median time from primary cancer, 21 years [range, 9-35 years]). SMNHPV sites included oropharynx (N = 44), anorectum (N = 6), uterine cervix (N = 2), and vulva (N = 2). The 33-year cumulative incidence was 0.3% (95% CI, 0.2%-0.4%), and the SIR was nearly 3-fold that of the general population (SIR, 2.86; 95% CI, 2.05-4.00). Female survivors were not at increased risk of cervical or vulvar cancers compared with the general population. All survivors had an elevated risk of oropharyngeal SMNHPV (males: SIR, 4.06; 95% CI, 2.37-6.97; females: SIR, 8.44; 95% CI 4.88-14.61) and anorectal SMNHPV (males: SIR, 13.56; 95% CI, 5.09-36.13; females: SIR, 9.15; 95% CI, 2.29-36.61). Males (vs females: rSIR, 1.99; 95% CI, 1.00-3.94); head, neck, and pelvic radiotherapy doses >3000 centigray (vs none: rSIR, 2.35; 95% CI, 1.11-4.97); and cisplatin-equivalent doses >400 mg/m2 (vs none: rSIR, 4.51; 95% CI, 1.78-11.43) were associated with increased SMNHPV SIRs in multivariable analysis. CONCLUSIONS: Childhood cancer survivors are at increased risk for SMN in sites susceptible to HPV-associated malignancies. Further research examining HPV in the etiology of SMN and the promotion of HPV vaccination and surveillance guidelines for SMNHPV in cancer survivors is warranted.
BACKGROUND: Human papillomavirus (HPV)-associated subsequent malignant neoplasms (SMNHPV ) in childhood cancer survivors are poorly understood. METHODS: The cumulative risk of SMNHPV was assessed among 24,363 Childhood Cancer Survivor Study participants. Standardized incidence ratios (SIRs) and absolute excess risk were calculated using age-matched, sex-matched, and calendar year rates from the Surveillance, Epidemiology, and End Results program. Poisson regression models identified SMNHPV risk factors, evaluating relative SIRs (rSIR) and 95% confidence intervals (95% CIs). RESULTS: In total, 46 survivors developed an SMNHPV (median age, 31 years [range, 10-56 years]; median time from primary cancer, 21 years [range, 9-35 years]). SMNHPV sites included oropharynx (N = 44), anorectum (N = 6), uterine cervix (N = 2), and vulva (N = 2). The 33-year cumulative incidence was 0.3% (95% CI, 0.2%-0.4%), and the SIR was nearly 3-fold that of the general population (SIR, 2.86; 95% CI, 2.05-4.00). Female survivors were not at increased risk of cervical or vulvar cancers compared with the general population. All survivors had an elevated risk of oropharyngeal SMNHPV (males: SIR, 4.06; 95% CI, 2.37-6.97; females: SIR, 8.44; 95% CI 4.88-14.61) and anorectal SMNHPV (males: SIR, 13.56; 95% CI, 5.09-36.13; females: SIR, 9.15; 95% CI, 2.29-36.61). Males (vs females: rSIR, 1.99; 95% CI, 1.00-3.94); head, neck, and pelvic radiotherapy doses >3000 centigray (vs none: rSIR, 2.35; 95% CI, 1.11-4.97); and cisplatin-equivalent doses >400 mg/m2 (vs none: rSIR, 4.51; 95% CI, 1.78-11.43) were associated with increased SMNHPV SIRs in multivariable analysis. CONCLUSIONS: Childhood cancer survivors are at increased risk for SMN in sites susceptible to HPV-associated malignancies. Further research examining HPV in the etiology of SMN and the promotion of HPV vaccination and surveillance guidelines for SMNHPV in cancer survivors is warranted.
Keywords:
cancer survivors; early detection of cancer; human papillomavirus (HPV)-associated malignancy; pediatric cancer; subsequent malignant neoplasms; survivorship care
Authors: Daniel M Green; Wei Liu; William H Kutteh; Raymond W Ke; Kyla C Shelton; Charles A Sklar; Wassim Chemaitilly; Ching-Hon Pui; James L Klosky; Sheri L Spunt; Monika L Metzger; DeoKumar Srivastava; Kirsten K Ness; Leslie L Robison; Melissa M Hudson Journal: Lancet Oncol Date: 2014-09-16 Impact factor: 41.316
Authors: Alexandra W van den Belt-Dusebout; Ronald de Wit; Jourik A Gietema; Simon Horenblas; Marieke W J Louwman; Jacques G Ribot; Harald J Hoekstra; Gabey M Ouwens; Berthe M P Aleman; Flora E van Leeuwen Journal: J Clin Oncol Date: 2007-10-01 Impact factor: 44.544
Authors: Gregory T Armstrong; Qi Liu; Yutaka Yasui; Joseph P Neglia; Wendy Leisenring; Leslie L Robison; Ann C Mertens Journal: J Clin Oncol Date: 2009-03-30 Impact factor: 44.544
Authors: Debra L Friedman; John Whitton; Wendy Leisenring; Ann C Mertens; Sue Hammond; Marilyn Stovall; Sarah S Donaldson; Anna T Meadows; Leslie L Robison; Joseph P Neglia Journal: J Natl Cancer Inst Date: 2010-07-15 Impact factor: 11.816